Bolt Biotherapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Bolt Biotherapeutics announces its 2026 Annual Meeting of Stockholders, to be held virtually on June 10, 2026, with key proposals including director elections and auditor ratification.
NASDAQ
DEF: Bolt Biotherapeutics Announces 2025 Annual Meeting of Stockholders, Proposes Reverse Stock Split
Bolt Biotherapeutics will hold its 2025 Annual Meeting of Stockholders virtually on May 27, 2025, to vote on director elections, auditor ratification, and a proposed reverse stock split.
NASDAQ
Bolt Biotherapeutics is seeking stockholder approval for a reverse stock split to meet Nasdaq's minimum bid price requirement and maintain its listing.
NASDAQ
Bolt Biotherapeutics disclosed a strategic pipeline prioritization and restructuring, leading to changes in its Board and executive leadership, including the departure of the CEO and CMO.
NASDAQ
Bolt Biotherapeutics will hold its annual stockholders meeting on June 12, 2024, to vote on the election of directors and the ratification of its independent auditor.
NASDAQ
DEF 14A: Bolt Biotherapeutics Sets Date for 2024 Annual Stockholders Meeting, Outlines Key Proposals
Bolt Biotherapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 12, 2024, to elect directors and ratify the selection of its independent accounting firm.